Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupNeuro-OncologyDiseaseBrain MetastasesSubgroupICD10C79.3MeSHSequenceChemotherapyChemo-substanceCisplatinTemozolomideChemo-substanceCisplatinTemozolomideChemo-substanceCisplatinTemozolomideChemo-substanceCisplatinTemozolomideNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideNo. Substances8Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaNeurotoxicityNeutropeniaRenal FailureThrombocytopenia below 50 000/µl only studiesPublicationAuthorChristodoulou CDiseaseHirnmetastasen bei solidem Tumor, ECOG 0-3OriginHenry Dunant Hospital, Athens, Greece, HeCOGProtocols in Revision 1 protocol foundProtocols under revision.Cisplatin 75 / Temozolomide 150, Brain Metastases (PID2833 V1.0)
